AbbVie Inc. Files 8-K on Officer Changes and Financials
Ticker: ABBV · Form: 8-K · Filed: Feb 14, 2025 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Feb 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, financials
Related Tickers: ABBV
TL;DR
AbbVie filed an 8-K on Feb 14th detailing exec changes and financial exhibits.
AI Summary
AbbVie Inc. filed an 8-K on February 14, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits, with the report date as of February 13, 2025.
Why It Matters
This filing provides crucial updates on AbbVie's corporate governance and executive appointments, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — This is a routine 8-K filing detailing corporate governance and financial information, not indicating any immediate operational or financial distress.
Key Numbers
- 20250214 — Filing Date (Date the 8-K was filed with the SEC.)
- 20250213 — Report Date (The date as of which the information in the report is current.)
Key Players & Entities
- AbbVie Inc. (company) — Filer
- 0001551152 (company) — Central Index Key
- ABBV (company) — Ticker Symbol
FAQ
What specific officer positions were affected by the appointments or departures mentioned in the filing?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and positions are not detailed in the provided excerpt.
Are there any new compensatory arrangements for officers disclosed in this filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item information, suggesting such details are included, though not explicitly stated in the excerpt.
What is the significance of the 'Regulation FD Disclosure' item?
This indicates that AbbVie is making public disclosures that could be considered material non-public information, ensuring fair disclosure to all investors.
What types of financial statements and exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific nature of these documents is not detailed in the provided text.
What is AbbVie Inc.'s Standard Industrial Classification (SIC) code?
AbbVie Inc.'s SIC code is 2834, which corresponds to 'Pharmaceutical Preparations'.
Filing Stats: 683 words · 3 min read · ~2 pages · Grade level 9.4 · Accepted 2025-02-14 07:30:58
Key Financial Figures
- $0.01 — e on which registered Common Stock, $0.01 Par Value ABBV New York Stock Excha
Filing Documents
- tm256372d1_8k.htm (8-K) — 43KB
- tm256372d1_ex99-1.htm (EX-99.1) — 11KB
- 0001104659-25-013467.txt ( ) — 307KB
- abbv-20250213.xsd (EX-101.SCH) — 4KB
- abbv-20250213_def.xml (EX-101.DEF) — 30KB
- abbv-20250213_lab.xml (EX-101.LAB) — 40KB
- abbv-20250213_pre.xml (EX-101.PRE) — 28KB
- tm256372d1_8k_htm.xml (XML) — 11KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On February 13, 2025, the Board of Directors (the "Board") of AbbVie Inc. (the "Company") unanimously elected Robert A. Michael to succeed Richard A. Gonzalez as the Company's Chairman, effective July 1, 2025. Mr. Gonzalez, who has served as Chairman since the Company's formation in 2013, will retire from the Board, effective July 1, 2025. Mr. Michael is the Company's current Chief Executive Officer, as well as a director on the Board. On February 13, 2025, Glenn F. Tilton informed the Company of his decision to retire as a director, effective July 1, 2025 .
01
Item 7.01 Regulation FD Disclosure. On February 14, 2025, the Company issued a press release announcing the appointment of Mr. Michael as Chairman, effective July 1, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing .
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press release issued by AbbVie Inc. on February 14, 2025. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. By: /s/ Perry C. Siatis Date: February 14, 2025 Name: Perry C. Siatis Title: Executive Vice President, General Counsel and Secretary